Research programme: multiple sclerosis therapy - Androclus Therapeutics
Alternative Names: AT-008Latest Information Update: 10 Mar 2011
Price :
$50 *
At a glance
- Originator Androclus Therapeutics
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 20 Sep 2006 This programme is still in active development
- 22 Jun 2005 This programme is still in active development - (BIO-2005)
- 02 Jul 2004 Preclinical trials in Multiple sclerosis in USA (PO)